| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 28 | 2022 | 207 | 10.100 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 14 | 2020 | 37 | 5.840 |
Why?
|
| alpha 1-Antitrypsin | 10 | 2020 | 61 | 3.460 |
Why?
|
| Asthma | 10 | 2019 | 345 | 3.310 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 7 | 2019 | 27 | 3.210 |
Why?
|
| Muscarinic Antagonists | 5 | 2019 | 54 | 2.390 |
Why?
|
| Lung | 11 | 2019 | 849 | 2.120 |
Why?
|
| Sleep Apnea, Obstructive | 7 | 2021 | 142 | 2.050 |
Why?
|
| Pulmonary Emphysema | 7 | 2017 | 71 | 1.880 |
Why?
|
| Bronchodilator Agents | 5 | 2019 | 43 | 1.450 |
Why?
|
| Lung Diseases, Interstitial | 5 | 2016 | 110 | 1.400 |
Why?
|
| Benzyl Alcohols | 2 | 2019 | 4 | 1.290 |
Why?
|
| Chlorobenzenes | 2 | 2019 | 8 | 1.290 |
Why?
|
| Androstadienes | 2 | 2019 | 41 | 1.280 |
Why?
|
| Bronchoscopy | 6 | 2016 | 147 | 1.150 |
Why?
|
| Genetic Testing | 5 | 2015 | 159 | 1.110 |
Why?
|
| Practice Patterns, Nurses' | 2 | 2015 | 16 | 1.040 |
Why?
|
| Bronchi | 2 | 2015 | 59 | 1.020 |
Why?
|
| Humans | 76 | 2022 | 68525 | 0.980 |
Why?
|
| Nurse Practitioners | 2 | 2015 | 90 | 0.970 |
Why?
|
| Drug Combinations | 3 | 2019 | 304 | 0.950 |
Why?
|
| Lung Diseases | 3 | 2017 | 175 | 0.940 |
Why?
|
| Islets of Langerhans | 7 | 2022 | 87 | 0.930 |
Why?
|
| Islets of Langerhans Transplantation | 7 | 2022 | 101 | 0.900 |
Why?
|
| Dyspnea | 4 | 2016 | 87 | 0.850 |
Why?
|
| Lymphangioleiomyomatosis | 3 | 2016 | 9 | 0.830 |
Why?
|
| Administration, Inhalation | 8 | 2019 | 187 | 0.770 |
Why?
|
| Middle Aged | 38 | 2019 | 21119 | 0.770 |
Why?
|
| Risk Factors | 15 | 2018 | 5719 | 0.760 |
Why?
|
| Self-Management | 1 | 2021 | 82 | 0.750 |
Why?
|
| Polysomnography | 3 | 2021 | 92 | 0.710 |
Why?
|
| Aged | 26 | 2019 | 14842 | 0.710 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 4 | 2022 | 63 | 0.680 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 94 | 0.650 |
Why?
|
| Sirolimus | 2 | 2016 | 118 | 0.650 |
Why?
|
| Blood Proteins | 1 | 2018 | 94 | 0.640 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2017 | 10 | 0.630 |
Why?
|
| Cognitive Dysfunction | 2 | 2018 | 176 | 0.620 |
Why?
|
| Adult | 27 | 2022 | 21375 | 0.620 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2017 | 45 | 0.620 |
Why?
|
| Female | 38 | 2019 | 38015 | 0.620 |
Why?
|
| Pneumonectomy | 5 | 2016 | 79 | 0.610 |
Why?
|
| Smoking | 6 | 2017 | 1449 | 0.600 |
Why?
|
| Quinuclidines | 1 | 2016 | 10 | 0.600 |
Why?
|
| Trypsin Inhibitors | 2 | 2015 | 15 | 0.590 |
Why?
|
| Cognition Disorders | 3 | 2015 | 342 | 0.590 |
Why?
|
| Exercise Tolerance | 5 | 2016 | 75 | 0.570 |
Why?
|
| Emphysema | 3 | 2016 | 32 | 0.570 |
Why?
|
| Male | 38 | 2019 | 37281 | 0.570 |
Why?
|
| Genetic Counseling | 2 | 2013 | 45 | 0.560 |
Why?
|
| Proteomics | 1 | 2018 | 246 | 0.560 |
Why?
|
| Respiratory Muscles | 1 | 2016 | 9 | 0.560 |
Why?
|
| Prevalence | 6 | 2019 | 1609 | 0.560 |
Why?
|
| Pleural Diseases | 2 | 2010 | 20 | 0.550 |
Why?
|
| Quadriceps Muscle | 1 | 2016 | 23 | 0.550 |
Why?
|
| Comorbidity | 7 | 2019 | 1425 | 0.550 |
Why?
|
| Desensitization, Immunologic | 1 | 2015 | 25 | 0.540 |
Why?
|
| Drug Hypersensitivity | 1 | 2015 | 35 | 0.540 |
Why?
|
| United States | 15 | 2019 | 7335 | 0.530 |
Why?
|
| Scleroderma, Systemic | 4 | 2016 | 446 | 0.530 |
Why?
|
| Tropanes | 1 | 2015 | 3 | 0.520 |
Why?
|
| Ethanolamines | 1 | 2015 | 33 | 0.520 |
Why?
|
| Glucocorticoids | 1 | 2016 | 222 | 0.520 |
Why?
|
| Sarcoidosis | 1 | 2015 | 77 | 0.510 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 331 | 0.510 |
Why?
|
| Cyclophosphamide | 3 | 2016 | 129 | 0.500 |
Why?
|
| Research Design | 2 | 2016 | 729 | 0.500 |
Why?
|
| Health Surveys | 3 | 2019 | 488 | 0.500 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 83 | 0.500 |
Why?
|
| Lower Extremity | 1 | 2016 | 153 | 0.490 |
Why?
|
| Cross-Sectional Studies | 5 | 2019 | 2264 | 0.480 |
Why?
|
| Sepsis | 2 | 2007 | 233 | 0.470 |
Why?
|
| Patient Readmission | 1 | 2016 | 267 | 0.470 |
Why?
|
| Mutation | 1 | 2018 | 1213 | 0.450 |
Why?
|
| Bronchiectasis | 1 | 2013 | 25 | 0.440 |
Why?
|
| Genotype | 5 | 2018 | 785 | 0.440 |
Why?
|
| Biomarkers | 1 | 2018 | 1593 | 0.440 |
Why?
|
| Patient Preference | 1 | 2013 | 57 | 0.430 |
Why?
|
| Insulin | 4 | 2019 | 617 | 0.430 |
Why?
|
| Hypertension, Pulmonary | 3 | 2005 | 232 | 0.420 |
Why?
|
| Pancreatitis, Chronic | 3 | 2019 | 168 | 0.420 |
Why?
|
| Prostheses and Implants | 2 | 2016 | 159 | 0.410 |
Why?
|
| Logistic Models | 4 | 2016 | 1419 | 0.410 |
Why?
|
| Registries | 1 | 2015 | 730 | 0.410 |
Why?
|
| Formoterol Fumarate | 3 | 2016 | 25 | 0.400 |
Why?
|
| Surveys and Questionnaires | 8 | 2021 | 2798 | 0.390 |
Why?
|
| Immunosuppressive Agents | 3 | 2016 | 514 | 0.390 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 424 | 0.380 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 938 | 0.380 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2016 | 2323 | 0.370 |
Why?
|
| Clinical Competence | 1 | 2015 | 657 | 0.360 |
Why?
|
| Intensive Care Units | 3 | 2007 | 344 | 0.350 |
Why?
|
| Quality of Life | 8 | 2021 | 1515 | 0.350 |
Why?
|
| Treatment Outcome | 12 | 2019 | 7028 | 0.340 |
Why?
|
| Phenotype | 3 | 2017 | 946 | 0.340 |
Why?
|
| Disease Progression | 4 | 2017 | 1037 | 0.340 |
Why?
|
| Respiratory Function Tests | 3 | 2018 | 123 | 0.330 |
Why?
|
| Palliative Care | 2 | 2008 | 271 | 0.320 |
Why?
|
| Brachial Plexus Neuritis | 1 | 2008 | 2 | 0.320 |
Why?
|
| Phrenic Nerve | 1 | 2008 | 4 | 0.320 |
Why?
|
| Spirometry | 4 | 2015 | 47 | 0.320 |
Why?
|
| Body Mass Index | 3 | 2016 | 866 | 0.320 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2008 | 37 | 0.310 |
Why?
|
| Paralysis | 1 | 2008 | 35 | 0.310 |
Why?
|
| Administrative Claims, Healthcare | 2 | 2019 | 7 | 0.310 |
Why?
|
| Leukocyte Count | 1 | 2007 | 94 | 0.310 |
Why?
|
| Fluticasone-Salmeterol Drug Combination | 3 | 2016 | 4 | 0.310 |
Why?
|
| Eosinophils | 1 | 2007 | 60 | 0.310 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2007 | 117 | 0.300 |
Why?
|
| South Carolina | 4 | 2021 | 2750 | 0.300 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2022 | 529 | 0.300 |
Why?
|
| Neuropsychological Tests | 4 | 2018 | 517 | 0.300 |
Why?
|
| Adolescent | 9 | 2019 | 8903 | 0.300 |
Why?
|
| Drug Therapy, Combination | 4 | 2016 | 648 | 0.290 |
Why?
|
| Neoplasms | 1 | 2018 | 1660 | 0.290 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2020 | 195 | 0.290 |
Why?
|
| Minors | 1 | 2006 | 3 | 0.290 |
Why?
|
| Neutrophils | 1 | 2007 | 204 | 0.290 |
Why?
|
| Feasibility Studies | 3 | 2022 | 652 | 0.280 |
Why?
|
| Adipose Tissue | 2 | 2017 | 221 | 0.280 |
Why?
|
| Budesonide | 2 | 2016 | 10 | 0.280 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2010 | 756 | 0.280 |
Why?
|
| Forced Expiratory Volume | 6 | 2016 | 87 | 0.270 |
Why?
|
| Prognosis | 5 | 2017 | 2093 | 0.260 |
Why?
|
| Cysts | 2 | 2016 | 70 | 0.260 |
Why?
|
| Hyperglycemia | 1 | 2006 | 158 | 0.260 |
Why?
|
| Connective Tissue Diseases | 1 | 2004 | 18 | 0.250 |
Why?
|
| Recovery of Function | 2 | 2019 | 506 | 0.250 |
Why?
|
| Epoprostenol | 2 | 2003 | 71 | 0.250 |
Why?
|
| Health Care Costs | 3 | 2016 | 346 | 0.240 |
Why?
|
| Population Surveillance | 2 | 2016 | 285 | 0.240 |
Why?
|
| Cough | 2 | 2015 | 65 | 0.240 |
Why?
|
| Time Factors | 5 | 2019 | 4655 | 0.240 |
Why?
|
| Pneumothorax | 2 | 2005 | 42 | 0.240 |
Why?
|
| Hypoglycemic Agents | 1 | 2006 | 361 | 0.230 |
Why?
|
| Self Care | 1 | 2006 | 252 | 0.230 |
Why?
|
| Aged, 80 and over | 4 | 2015 | 4843 | 0.230 |
Why?
|
| Smoking Cessation | 3 | 2022 | 1032 | 0.220 |
Why?
|
| Heterozygote | 2 | 2017 | 174 | 0.220 |
Why?
|
| Pneumonia | 3 | 2016 | 110 | 0.210 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 2017 | 48 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 785 | 0.210 |
Why?
|
| Technology | 1 | 2021 | 24 | 0.210 |
Why?
|
| Sex Factors | 2 | 2016 | 1265 | 0.210 |
Why?
|
| Pilot Projects | 3 | 2021 | 1341 | 0.200 |
Why?
|
| Age Distribution | 2 | 2016 | 319 | 0.200 |
Why?
|
| Age Factors | 2 | 2016 | 1860 | 0.190 |
Why?
|
| Cohort Studies | 5 | 2018 | 2356 | 0.190 |
Why?
|
| Prospective Studies | 6 | 2016 | 3702 | 0.190 |
Why?
|
| Insulin-Secreting Cells | 2 | 2019 | 41 | 0.190 |
Why?
|
| Animals | 10 | 2022 | 20877 | 0.190 |
Why?
|
| Antihypertensive Agents | 2 | 2003 | 497 | 0.190 |
Why?
|
| Self Report | 3 | 2016 | 370 | 0.180 |
Why?
|
| Hemothorax | 1 | 1999 | 9 | 0.180 |
Why?
|
| Carbon Monoxide | 1 | 2019 | 58 | 0.180 |
Why?
|
| Clathrin | 1 | 2019 | 17 | 0.180 |
Why?
|
| Behavioral Risk Factor Surveillance System | 2 | 2016 | 73 | 0.170 |
Why?
|
| Cytokines | 3 | 2019 | 866 | 0.170 |
Why?
|
| Endocytosis | 1 | 2019 | 113 | 0.170 |
Why?
|
| Health Status | 2 | 2016 | 429 | 0.170 |
Why?
|
| Ceruloplasmin | 1 | 2018 | 8 | 0.170 |
Why?
|
| Angiopoietin-1 | 1 | 2018 | 12 | 0.170 |
Why?
|
| Mass Screening | 2 | 2015 | 837 | 0.160 |
Why?
|
| Health Care Surveys | 1 | 2019 | 239 | 0.160 |
Why?
|
| Serine Endopeptidases | 1 | 2018 | 50 | 0.160 |
Why?
|
| Cathepsin B | 1 | 2018 | 33 | 0.160 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2018 | 58 | 0.160 |
Why?
|
| Adiponectin | 1 | 2018 | 52 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 114 | 0.160 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 88 | 0.160 |
Why?
|
| Gene-Environment Interaction | 1 | 2017 | 31 | 0.160 |
Why?
|
| Cost of Illness | 1 | 2019 | 204 | 0.150 |
Why?
|
| Homozygote | 1 | 2017 | 119 | 0.150 |
Why?
|
| Hemodynamics | 1 | 2000 | 705 | 0.150 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 319 | 0.150 |
Why?
|
| Gene Frequency | 1 | 2017 | 207 | 0.150 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2017 | 35 | 0.150 |
Why?
|
| Cause of Death | 1 | 2018 | 241 | 0.150 |
Why?
|
| Graft Survival | 4 | 2022 | 465 | 0.150 |
Why?
|
| Mortality | 1 | 2018 | 162 | 0.150 |
Why?
|
| Reference Values | 1 | 2018 | 579 | 0.150 |
Why?
|
| Linear Models | 2 | 2015 | 521 | 0.150 |
Why?
|
| Undifferentiated Connective Tissue Diseases | 1 | 2016 | 1 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 170 | 0.140 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 1172 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 445 | 0.140 |
Why?
|
| Mycophenolic Acid | 1 | 2016 | 62 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 5 | 2022 | 2790 | 0.140 |
Why?
|
| Ablation Techniques | 1 | 2016 | 33 | 0.140 |
Why?
|
| Apoptosis | 3 | 2019 | 1640 | 0.140 |
Why?
|
| Muscle Fatigue | 1 | 2016 | 16 | 0.140 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 955 | 0.140 |
Why?
|
| Hospitalization | 3 | 2016 | 977 | 0.140 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2015 | 15 | 0.140 |
Why?
|
| Young Adult | 3 | 2016 | 5708 | 0.140 |
Why?
|
| Stem Cells | 1 | 2017 | 248 | 0.140 |
Why?
|
| Protective Factors | 1 | 2015 | 24 | 0.130 |
Why?
|
| Sex Distribution | 1 | 2016 | 272 | 0.130 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2016 | 82 | 0.130 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2015 | 333 | 0.130 |
Why?
|
| Budesonide, Formoterol Fumarate Drug Combination | 1 | 2015 | 1 | 0.130 |
Why?
|
| Insurance Claim Review | 1 | 2015 | 39 | 0.130 |
Why?
|
| Pancreatitis | 1 | 2017 | 279 | 0.130 |
Why?
|
| Selection Bias | 1 | 2015 | 23 | 0.130 |
Why?
|
| Multiple Organ Failure | 2 | 2013 | 36 | 0.130 |
Why?
|
| Mice, Inbred NOD | 3 | 2020 | 138 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2017 | 880 | 0.130 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 85 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2018 | 621 | 0.130 |
Why?
|
| Retrospective Studies | 7 | 2016 | 7264 | 0.130 |
Why?
|
| Commerce | 1 | 2015 | 80 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2015 | 689 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2015 | 411 | 0.130 |
Why?
|
| Postal Service | 1 | 2014 | 19 | 0.130 |
Why?
|
| Likelihood Functions | 1 | 2015 | 105 | 0.130 |
Why?
|
| Genomics | 1 | 2015 | 167 | 0.120 |
Why?
|
| Microbiota | 1 | 2015 | 79 | 0.120 |
Why?
|
| Pain | 2 | 2008 | 472 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2015 | 219 | 0.120 |
Why?
|
| Drug Interactions | 1 | 2015 | 289 | 0.120 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2015 | 127 | 0.120 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 174 | 0.120 |
Why?
|
| Medicare | 1 | 2016 | 316 | 0.120 |
Why?
|
| Insurance, Health | 1 | 2015 | 200 | 0.120 |
Why?
|
| Dementia | 1 | 2015 | 158 | 0.120 |
Why?
|
| Blood Glucose | 3 | 2017 | 631 | 0.120 |
Why?
|
| Smoking Prevention | 1 | 2015 | 259 | 0.120 |
Why?
|
| Disease Management | 1 | 2015 | 248 | 0.120 |
Why?
|
| Dry Powder Inhalers | 1 | 2013 | 4 | 0.120 |
Why?
|
| Hyperlipoproteinemia Type I | 1 | 2013 | 3 | 0.110 |
Why?
|
| Respiratory Sounds | 1 | 2013 | 35 | 0.110 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2013 | 34 | 0.110 |
Why?
|
| Biopsy | 1 | 2015 | 539 | 0.110 |
Why?
|
| Hemorrhage | 1 | 2015 | 328 | 0.110 |
Why?
|
| Hereditary Angioedema Type III | 1 | 2012 | 3 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 212 | 0.110 |
Why?
|
| Abdomen, Acute | 1 | 2012 | 14 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 848 | 0.110 |
Why?
|
| Infusions, Intravenous | 2 | 2005 | 334 | 0.110 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 396 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1046 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2015 | 2004 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2015 | 322 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2014 | 402 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 467 | 0.100 |
Why?
|
| Child | 3 | 2015 | 6400 | 0.100 |
Why?
|
| Organizational Innovation | 1 | 2011 | 55 | 0.100 |
Why?
|
| Bronchial Diseases | 1 | 2010 | 9 | 0.100 |
Why?
|
| Mice | 5 | 2022 | 8472 | 0.100 |
Why?
|
| Infant | 3 | 2006 | 2891 | 0.100 |
Why?
|
| Child, Preschool | 3 | 2006 | 3185 | 0.090 |
Why?
|
| Exercise | 1 | 2016 | 657 | 0.090 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2010 | 33 | 0.090 |
Why?
|
| Caregivers | 1 | 2013 | 365 | 0.090 |
Why?
|
| Genetic Carrier Screening | 2 | 2007 | 25 | 0.090 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 1851 | 0.090 |
Why?
|
| Infant, Newborn | 2 | 2006 | 2453 | 0.090 |
Why?
|
| Respiratory Tract Infections | 1 | 2010 | 91 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2016 | 1737 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2013 | 1329 | 0.080 |
Why?
|
| Mice, SCID | 2 | 2020 | 238 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2016 | 186 | 0.080 |
Why?
|
| Transplantation, Autologous | 2 | 2019 | 145 | 0.080 |
Why?
|
| Eisenmenger Complex | 1 | 2008 | 4 | 0.080 |
Why?
|
| Splenomegaly | 1 | 2008 | 13 | 0.080 |
Why?
|
| Diaphragmatic Eventration | 1 | 2008 | 9 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2017 | 2688 | 0.080 |
Why?
|
| Arm | 1 | 2008 | 59 | 0.080 |
Why?
|
| Vital Capacity | 1 | 2007 | 43 | 0.080 |
Why?
|
| Pancreatectomy | 2 | 2019 | 129 | 0.080 |
Why?
|
| Obesity | 1 | 2015 | 1074 | 0.080 |
Why?
|
| Tomography, Spiral Computed | 1 | 2007 | 57 | 0.080 |
Why?
|
| Coculture Techniques | 2 | 2017 | 147 | 0.080 |
Why?
|
| Radiography, Interventional | 1 | 2007 | 49 | 0.070 |
Why?
|
| Macrophages | 2 | 2022 | 647 | 0.070 |
Why?
|
| Prosthesis Design | 1 | 2007 | 301 | 0.070 |
Why?
|
| Clinical Protocols | 1 | 2006 | 172 | 0.070 |
Why?
|
| Confidentiality | 1 | 2006 | 62 | 0.070 |
Why?
|
| Lung Volume Measurements | 2 | 2016 | 19 | 0.070 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2005 | 32 | 0.070 |
Why?
|
| Waiting Lists | 1 | 2005 | 104 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2006 | 281 | 0.060 |
Why?
|
| Dermatomyositis | 1 | 2004 | 31 | 0.060 |
Why?
|
| Hypoxia | 1 | 2005 | 169 | 0.060 |
Why?
|
| Exercise Test | 1 | 2005 | 242 | 0.060 |
Why?
|
| Lung Transplantation | 1 | 2005 | 88 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 626 | 0.060 |
Why?
|
| Fees, Pharmaceutical | 1 | 2003 | 7 | 0.060 |
Why?
|
| Physical Examination | 1 | 2004 | 152 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2005 | 193 | 0.060 |
Why?
|
| Markov Chains | 1 | 2003 | 133 | 0.060 |
Why?
|
| Parents | 1 | 2006 | 309 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2013 | 3256 | 0.060 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2004 | 155 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2006 | 403 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2003 | 141 | 0.060 |
Why?
|
| Electronics | 1 | 2022 | 25 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2003 | 191 | 0.050 |
Why?
|
| Liver Transplantation | 1 | 2005 | 400 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 772 | 0.050 |
Why?
|
| Cystic Fibrosis | 1 | 2005 | 283 | 0.050 |
Why?
|
| Total Lung Capacity | 1 | 2000 | 14 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2007 | 766 | 0.050 |
Why?
|
| Echocardiography, Doppler | 1 | 2000 | 87 | 0.050 |
Why?
|
| Macrophage Activation | 1 | 2020 | 75 | 0.050 |
Why?
|
| Cardiac Output | 1 | 2000 | 133 | 0.050 |
Why?
|
| Chemokines, CC | 1 | 2019 | 18 | 0.050 |
Why?
|
| Glucose Tolerance Test | 1 | 2019 | 75 | 0.050 |
Why?
|
| Glucose Intolerance | 1 | 2019 | 36 | 0.050 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2020 | 145 | 0.050 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2000 | 102 | 0.040 |
Why?
|
| Chlorpromazine | 1 | 2019 | 7 | 0.040 |
Why?
|
| Chemokine CXCL12 | 1 | 2019 | 51 | 0.040 |
Why?
|
| Cytoprotection | 1 | 2019 | 39 | 0.040 |
Why?
|
| Pleural Effusion | 1 | 1999 | 74 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2019 | 192 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 247 | 0.040 |
Why?
|
| Cardiac Catheterization | 1 | 2000 | 419 | 0.040 |
Why?
|
| Tissue Survival | 1 | 2017 | 22 | 0.040 |
Why?
|
| Ceruletide | 1 | 2017 | 8 | 0.040 |
Why?
|
| Acinar Cells | 1 | 2017 | 8 | 0.040 |
Why?
|
| Amylases | 1 | 2017 | 17 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2017 | 31 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 2017 | 78 | 0.040 |
Why?
|
| Kinetics | 1 | 2019 | 1047 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 58 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2017 | 191 | 0.040 |
Why?
|
| Antithrombin III | 1 | 2017 | 23 | 0.040 |
Why?
|
| Thromboplastin | 1 | 2017 | 21 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2017 | 200 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 110 | 0.040 |
Why?
|
| Peptide Hydrolases | 1 | 2017 | 82 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 122 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2017 | 87 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2022 | 702 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2017 | 140 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2017 | 242 | 0.040 |
Why?
|
| Survival Rate | 1 | 1999 | 1055 | 0.040 |
Why?
|
| Cell Survival | 1 | 2019 | 901 | 0.040 |
Why?
|
| Pancreas | 1 | 2017 | 225 | 0.040 |
Why?
|
| Pulmonary Ventilation | 1 | 2016 | 28 | 0.030 |
Why?
|
| Tiotropium Bromide | 1 | 2015 | 2 | 0.030 |
Why?
|
| Scopolamine Derivatives | 1 | 2015 | 3 | 0.030 |
Why?
|
| Cell Death | 1 | 2017 | 329 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 244 | 0.030 |
Why?
|
| Insurance Claim Reporting | 1 | 2015 | 10 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 330 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 249 | 0.030 |
Why?
|
| Postmenopause | 1 | 2015 | 92 | 0.030 |
Why?
|
| Data Mining | 1 | 2015 | 45 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 498 | 0.030 |
Why?
|
| Incidence | 1 | 1999 | 1582 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 130 | 0.030 |
Why?
|
| Models, Biological | 1 | 2019 | 981 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 770 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2017 | 432 | 0.030 |
Why?
|
| Acute Disease | 1 | 2016 | 658 | 0.030 |
Why?
|
| Cell Movement | 1 | 2017 | 630 | 0.030 |
Why?
|
| Mitochondria | 1 | 2019 | 643 | 0.030 |
Why?
|
| Perfusion Imaging | 1 | 2013 | 27 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2017 | 1199 | 0.030 |
Why?
|
| Inpatients | 1 | 2015 | 208 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2015 | 275 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 791 | 0.030 |
Why?
|
| Blood Viscosity | 1 | 2013 | 9 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 2013 | 18 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2015 | 339 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2017 | 1034 | 0.030 |
Why?
|
| Remission, Spontaneous | 1 | 2012 | 25 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1054 | 0.030 |
Why?
|
| Triglycerides | 1 | 2013 | 184 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2015 | 374 | 0.030 |
Why?
|
| Health Behavior | 1 | 2015 | 458 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 693 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2015 | 621 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1465 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 1753 | 0.020 |
Why?
|
| Neuroimaging | 1 | 2012 | 122 | 0.020 |
Why?
|
| Ethanol | 1 | 2017 | 892 | 0.020 |
Why?
|
| Inflammation | 1 | 2017 | 1030 | 0.020 |
Why?
|
| Wakefulness | 1 | 2010 | 75 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2077 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 948 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 711 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1194 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2011 | 383 | 0.020 |
Why?
|
| Cholecystitis, Acute | 1 | 2008 | 4 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 1026 | 0.020 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 24 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2008 | 164 | 0.020 |
Why?
|
| Spleen | 1 | 2008 | 301 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2010 | 378 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2008 | 419 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2003 | 105 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2003 | 929 | 0.010 |
Why?
|